These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

583 related articles for article (PubMed ID: 10900877)

  • 21. COX-2 inhibitors.
    Brooks PM; Day RO
    Med J Aust; 2000 Oct; 173(8):433-6. PubMed ID: 11090038
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective COX-2 inhibition.
    Silas S; Clegg DO
    Bull Rheum Dis; 1999; 48(2):1-4. PubMed ID: 12024416
    [No Abstract]   [Full Text] [Related]  

  • 23. [Specific inhibitors of cyclooxygenase type 2] ].
    Tomasová-Studýnková J
    Vnitr Lek; 2002 May; 48(5):403-8. PubMed ID: 12061207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Mobility and quality of life for arthrosis and rheumatism patients. Modern pain management with selective cox-2 inhibition].
    MMW Fortschr Med; 2002 Jul; 144(29-30):52. PubMed ID: 12219613
    [No Abstract]   [Full Text] [Related]  

  • 25. The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex).
    Wynn RL
    Gen Dent; 2000; 48(1):16-20. PubMed ID: 11199547
    [No Abstract]   [Full Text] [Related]  

  • 26. Summaries for patients. The cost-effectiveness of cyclooxygenase-2 inhibitors for treating chronic arthritis.
    Ann Intern Med; 2003 May; 138(10):I39. PubMed ID: 12755582
    [No Abstract]   [Full Text] [Related]  

  • 27. [Role of cyclooxygenase-2 (COG-2) in the etiology of pain].
    Nasonova VA
    Ter Arkh; 2001; 73(5):56-7. PubMed ID: 11517752
    [No Abstract]   [Full Text] [Related]  

  • 28. [Specific COX-2 inhibitors: prospects of therapy with new analgesic and anti-inflammatory substances].
    Hinz B; Brune K
    Wien Klin Wochenschr; 1999 Feb; 111(3):103-12. PubMed ID: 10093892
    [TBL] [Abstract][Full Text] [Related]  

  • 29. COX-2 inhibitors: better than traditional NSAIDs? Vioxx and Celebrex may be no less risky than NSAIDs.
    Atkinson HG
    Health News; 2002 Aug; 8(8):5. PubMed ID: 12206146
    [No Abstract]   [Full Text] [Related]  

  • 30. [Financial interests characterize published reports on coxiber. Whom can we rely on?].
    Håkansson J
    Lakartidningen; 2002 Oct; 99(40):3930-1. PubMed ID: 12422746
    [No Abstract]   [Full Text] [Related]  

  • 31. New versus old drugs for arthritis.
    Health News; 1999 Nov; 5(14):7. PubMed ID: 10624169
    [No Abstract]   [Full Text] [Related]  

  • 32. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [New nonsteroidal antirheumatic drugs].
    Forster A; Michel BA
    Praxis (Bern 1994); 2000 May; 89(20):855-60. PubMed ID: 10865508
    [No Abstract]   [Full Text] [Related]  

  • 34. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
    Geis GS
    Scand J Rheumatol Suppl; 1999; 109():31-7. PubMed ID: 10422544
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Current status of COX II inhibitors in therapy of rheumatoid arthritis in comparison with conventional non-steroidal anti-inflammatory agents. Attempt at an evaluation with regard to evidence-based medicine].
    Krüger K
    Z Rheumatol; 2001 Dec; 60(6):481-4. PubMed ID: 11826746
    [No Abstract]   [Full Text] [Related]  

  • 38. [No loss of effectiveness with rofecoxib. Long-term control of rheumatoid pain].
    Einecke D
    MMW Fortschr Med; 2002 Nov; 144(46):68. PubMed ID: 12534087
    [No Abstract]   [Full Text] [Related]  

  • 39. COX-2 inhibitors--a lesson in unexpected problems.
    Drazen JM
    N Engl J Med; 2005 Mar; 352(11):1131-2. PubMed ID: 15713947
    [No Abstract]   [Full Text] [Related]  

  • 40. [Adverse effect-free analgesia. New COX-2 inhibitor is even more selective].
    MMW Fortschr Med; 2003 May; 145(18):54. PubMed ID: 12808824
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.